PRIMARY MYELOFIBROSIS

This study tests whether adding a new drug (pelabresib) to the standard treatment (ruxolitinib) works better than the standard treatment alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not received prior JAK inhibitor therapy will take …

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests a drug called canakinumab in people with myelofibrosis, a rare bone marrow disorder. The goal is to see if it can improve symptoms, reduce spleen size, or help with anemia. About 14 adults will receive injections every 3 weeks for 6 months. The study is currently…

This study tests a drug called elotuzumab in 15 adults with a type of bone marrow cancer called myelofibrosis that has a specific genetic mutation (JAK2). The goal is to see if the drug can shrink an enlarged spleen, improve anemia, and reduce symptoms. Participants receive the d…

This study tested a drug called decitabine in 21 people with myelofibrosis, a rare bone marrow cancer that causes scarring and severe anemia. The goal was to see if the drug could improve blood counts and reduce the need for transfusions. Decitabine works by blocking certain prot…

This study checks the long-term safety of the drug ruxolitinib (given alone or with panobinostat) in people with certain blood or immune conditions like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already b…

This study gives people with myelofibrosis continued access to the drug momelotinib after they finish a previous trial. The goal is to monitor long-term safety and see how long patients live. About 237 adults who are already taking momelotinib without their disease getting worse …

This study tests a drug called pacritinib against standard treatments in about 400 people with myelofibrosis, a type of bone marrow cancer, who also have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and improve symptoms like bell…

This study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can help prevent graft-versus-host disease (GVHD) in people with myelofibrosis. About 53 adults with intermediate- or high-risk myelofibrosis will receive ruxolitinib to re…

This study tests the drug fedratinib in about 31 Japanese adults with a bone marrow cancer called myelofibrosis. The goal is to see if it safely shrinks an enlarged spleen and controls the disease. Participants take the drug daily, and doctors monitor side effects and response ov…